Ultraviolet Therapy of Atopic Eczema
Recent results from a pilot study have suggested that irradiation of patients with high doses of ultraviolet A1 radiation (UVA-1; 340–400 nm) may be effectively used as a monotherapy in the management of severe exacerbation of atopic dermatitis . This assumption has recently been confirmed in a multicenter trial . Accordingly, in this three-branched, randomized trial, atopic dermatitis patients were treated either with high-dose UVAi (10 days, 130 J/cm2/day; n = 20), or topically with fluocortolon (10 days, 1X daily; n = 17), or with conventional UVA-UVB therapy (10 days, 1 x daily, minimal effective dose-dependent; n = 16). By employing an established clinical scoring system, significant differences in favor of high-dose UVAi as well as fluocortolon therapy were observed (p<0.0001), as compared to UVA-UVB therapy. After 10 days, high-dose UVAi was found to be superior to fluocortolon (p<o.oo2). These clinical changes were reflected by concomitant changes in laboratory parameters. a sinificant reduction of elevated serum levels of eosinophilic cationic protein as well as of the blood eosinophil count was observed in patients undergoing high-dose UVA1 irradiation or fluocortolon treatment, but not UVA-UVB theraphy. These studies confirm the therapeutic effectiveness of high-dose UVA1 irradiation in the management of patients with atopic dermatis.
KeywordsAtopic Dermatitis Eosinophilic Cationic Protein Atopic Dermatitis Patient Blood Eosinophil Count Atopy Patch Test
- 2.Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Soennichsen N, Czech W, Kapp A, Stege H, Grewe M, Schöpf E: High-dose-UVAl therapy for atopic dermatitis. J Invest Dermatol 104: 564, 1995Google Scholar